Subjects: INFARTO DO MIOCÁRDIO (TRATAMENTO), ISQUEMIA MIOCÁRDICA
ABNT
MARIN-NETO, José Antônio. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet, v. 358, n. 9282, p. 605-613, 2001Tradução . . Acesso em: 08 nov. 2024.APA
Marin-Neto, J. A. (2001). Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet, 358( 9282), 605-613.NLM
Marin-Neto JA. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001 ; 358( 9282): 605-613.[citado 2024 nov. 08 ]Vancouver
Marin-Neto JA. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001 ; 358( 9282): 605-613.[citado 2024 nov. 08 ]